Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
about
Disease risk score as a confounder summary method: systematic review and recommendationsCharacteristics of patients initiating raloxifene compared to those initiating bisphosphonates.Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases.Confounder summary scores when comparing the effects of multiple drug exposuresLongitudinal change in clinical fracture incidence after initiation of bisphosphonatesPerformance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases.Initiation of rheumatoid arthritis treatments and the risk of serious infections.Osteoporosis therapies: evidence from health-care databases and observational population studies.Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.Fractures in women treated with raloxifene or alendronate: a retrospective database analysisRisedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsAdherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults.Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort studySSRI use and risk of fractures among perimenopausal women without mental disorders.Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion.Performance of the disease risk score in a cohort study with policy-induced selection bias.Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis.Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.Fractures and mortality in relation to different osteoporosis treatments.Osteoporosis prescribing trends in primary care: a population-based retrospective cohort study.Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP DatabaseImmediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study
P2860
Q26999267-9F522558-B2F2-4802-8A60-7CDBBE4106C2Q33395511-81DFB0A2-F150-4944-A435-868C6894A94DQ33511653-A097449E-03D0-42C3-8CF2-5234617F5D7FQ33566259-877975A4-9EC6-4D12-8285-B7B71190F0E4Q33819111-92BDF7A9-1C55-4F7E-A927-741F6D9B67F0Q33934896-3136B4C0-8CD8-4694-8918-8AB262109BB4Q34019267-03C0C327-ECAE-4BE1-9665-AE1A2996907AQ34242906-9075C5D7-2FCF-4003-BE02-709CE1E7B73AQ34272056-9B9C6A44-80BF-4F61-8DA1-3B1097990013Q34632451-B573CB65-4A65-403C-A294-555F2EC98036Q35678676-62C1628A-92DF-4335-88B9-5B9AE5F631ACQ35693057-80D1D366-D02C-4B9B-BC94-D997BC53CDEDQ35751984-917CDC55-AD5C-49E4-92F8-6C39ADD39FC7Q37329089-49F23E3E-D613-435D-957E-6186A5FB153BQ37701830-88572CCC-BFE9-4192-9C93-49E3E478A40FQ38991264-C97E5018-51B4-487B-9018-FD3CCDE54021Q39061355-44746934-7DAD-4003-86E9-6B9AB1C3907CQ39835356-6AF747BF-6117-43BB-8F02-8DABBAF4BE71Q40361680-88C7B85A-2A8D-4AD9-9041-8E321B174E1AQ42108489-A0630EDD-7EDB-42E8-9034-EEFFF4E08187Q43120315-C45998F9-5BDF-4FE7-9840-97C540A637B7Q43166707-7FFDA329-64DA-4B58-8F4B-60026F6747AEQ43577539-460B5011-A8AC-43C6-9DF1-41499A0170F6Q43813704-DCD1BB4F-E2C1-40AA-8EB4-3D9DA5B5AB66Q44336846-24224328-C208-44EC-A955-58FBE72A0981Q44381104-8AF5CA4E-65A1-4091-997C-E021590DB754Q44574043-72E2FE09-5145-4563-9153-8FF2FE18082AQ46244082-86DE820B-5353-47AA-9904-C614AC201E40Q51736759-7A8E03AA-AF20-4203-A569-A8B56FB74F84Q55090882-F831EA03-9588-4F6E-A88D-623FB9C28A7DQ57816528-0118F21E-A0F3-4373-B070-F3B05AA5B111Q58160099-95C7BA87-0679-4AF9-A069-B7B28BC13273
P2860
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@ast
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@en
type
label
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@ast
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@en
prefLabel
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@ast
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@en
P2093
P2860
P1476
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
@en
P2093
Daniel H Solomon
Jeffrey N Katz
Margaret R Stedman
Suzanne M Cadarette
P2860
P304
P356
10.7326/0003-4819-148-9-200805060-00003
P407
P577
2008-05-01T00:00:00Z